
## Michael P Busch

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3087694/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature, 2009, 461, 798-801.	13.7	2,001
2	The Risk of Transfusion-Transmitted Viral Infections. New England Journal of Medicine, 1996, 334, 1685-1690.	13.9	1,748
3	Dynamics of HIV viremia and antibody seroconversion in plasma donors. Aids, 2003, 17, 1871-1879.	1.0	1,107
4	The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma–associated herpesvirus): Distribution of infection in KS risk groups and evidence for sexual transmission. Nature Medicine, 1996, 2, 918-924.	15.2	752
5	Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet, The, 2021, 397, 452-455.	6.3	720
6	Detection of HIV-1 and HCV Infections among Antibody-Negative Blood Donors by Nucleic Acid–Amplification Testing. New England Journal of Medicine, 2004, 351, 760-768.	13.9	474
7	Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. Science, 2021, 371, 288-292.	6.0	412
8	Kinetics of fetal cellular and cell-free DNA in the maternal circulation during and after pregnancy: implications for noninvasive prenatal diagnosis. Transfusion, 2001, 41, 1524-1530.	0.8	244
9	Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion, 2003, 43, 788-798.	0.8	241
10	Screening the Blood Supply for West Nile Virus RNA by Nucleic Acid Amplification Testing. New England Journal of Medicine, 2005, 353, 460-467.	13.9	208
11	Infectivity of human immunodeficiency virusâ€1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion, 2009, 49, 2454-2489.	0.8	196
12	Virus and Antibody Dynamics in Acute West Nile Virus Infection. Journal of Infectious Diseases, 2008, 198, 984-993.	1.9	193
13	Genome-Wide Association Study of Spontaneous Resolution of Hepatitis C Virus Infection: Data From Multiple Cohorts. Annals of Internal Medicine, 2013, 158, 235.	2.0	187
14	Dynamics of viremia in early hepatitis C virus infection. Transfusion, 2005, 45, 994-1002.	0.8	174
15	Ethnicity, sex, and age are determinants of red blood cell storage and stress hemolysis: results of the REDS-III RBC-Omics study. Blood Advances, 2017, 1, 1132-1141.	2.5	164
16	Prevention of transfusion-transmitted infections. Blood, 2019, 133, 1854-1864.	0.6	164
17	Analysis of SARS-CoV-2 antibodies in COVID-19 convalescent blood using a coronavirus antigen microarray. Nature Communications, 2021, 12, 6.	5.8	164
18	Modeling sequence evolution in acute HIV-1 infection. Journal of Theoretical Biology, 2009, 261, 341-360.	0.8	162

#	Article	IF	CITATIONS
19	Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021. JAMA - Journal of the American Medical Association, 2021, 326, 1400.	3.8	160
20	Transfusionâ€associated infections: 50 years of relentless challenges and remarkable progress. Transfusion, 2010, 50, 2080-2099.	0.8	159
21	Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans. Journal of Virology, 2017, 91, .	1.5	148
22	Ten-Year Incidence of Chagas Cardiomyopathy Among Asymptomatic <i>Trypanosoma cruzi</i> –Seropositive Former Blood Donors. Circulation, 2013, 127, 1105-1115.	1.6	145
23	Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository. Aids, 2014, 28, 2439-2449.	1.0	133
24	West Nile Virus Infections Projected from Blood Donor Screening Data, United States, 2003. Emerging Infectious Diseases, 2006, 12, 395-402.	2.0	131
25	SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood. Nature Communications, 2020, 11, 4698.	5.8	124
26	Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. Aids, 2010, 24, 2763-2771.	1.0	121
27	International application of the Incidence Rate/Window Period model. Transfusion, 2002, 42, 966-972.	0.8	120
28	SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. Science Advances, 2021, 7, .	4.7	117
29	Transfusion-Transmitted Dengue and Associated Clinical Symptoms During the 2012 Epidemic in Brazil. Journal of Infectious Diseases, 2016, 213, 694-702.	1.9	114
30	Zika Virus Tissue and Blood Compartmentalization in Acute Infection of Rhesus Macaques. PLoS ONE, 2017, 12, e0171148.	1.1	102
31	Donor sex, age and ethnicity impact stored red blood cell antioxidant metabolism through mechanisms in part explained by glucose 6-phosphate dehydrogenase levels and activity. Haematologica, 2021, 106, 1290-1302.	1.7	95
32	Failure to Confirm XMRV/MLVs in the Blood of Patients with Chronic Fatigue Syndrome: A Multi-Laboratory Study. Science, 2011, 334, 814-817.	6.0	93
33	Development of a New Less-Sensitive Enzyme Immunoassay for Detection of Early HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 349-355.	0.9	87
34	High Incidence of Chikungunya Virus and Frequency of Viremic Blood Donations during Epidemic, Puerto Rico, USA, 2014. Emerging Infectious Diseases, 2016, 22, 1221-1228.	2.0	87
35	The <scp>N</scp> ational <scp>H</scp> eart, <scp>L</scp> ung, and <scp>B</scp> lood <scp>I</scp> nstitute <scp>R</scp> ecipient <scp>E</scp> pidemiology and <scp>D</scp> onor <scp>E</scp> valuation <scp>S</scp> tudy ( <scp>REDS</scp> â€ <scp>III</scp> ): a research program striving to improve blood donor and transfusion recipient outcomes. Transfusion. 2014, 54, 942-955.	0.8	85
36	Effect of donor, component, and recipient characteristics on hemoglobin increments following red blood cell transfusion. Blood, 2019, 134, 1003-1013.	0.6	82

#	Article	IF	CITATIONS
37	Quantitation of HTLV-I and II proviral load using real-time quantitative PCR with SYBR Green chemistry. Journal of Clinical Virology, 2004, 31, 275-282.	1.6	78
38	Viral load criteria and threshold optimization to improve HIV incidence assay characteristics. Aids, 2016, 30, 2361-2371.	1.0	78
39	Zika virus preferentially replicates in the female reproductive tract after vaginal inoculation of rhesus macaques. PLoS Pathogens, 2017, 13, e1006537.	2.1	78
40	Viral Surveillance in Serum Samples From Patients With Acute Liver Failure By Metagenomic Next-Generation Sequencing. Clinical Infectious Diseases, 2017, 65, 1477-1485.	2.9	76
41	Screening of Blood Donations for Zika Virus Infection — Puerto Rico, April 3–June 11, 2016. Morbidity and Mortality Weekly Report, 2016, 65, 627-628.	9.0	75
42	Cutting Edge: Transcriptional Profiling Reveals Multifunctional and Cytotoxic Antiviral Responses of Zika Virus–Specific CD8+ T Cells. Journal of Immunology, 2018, 201, 3487-3491.	0.4	70
43	<scp>W</scp> est <scp>N</scp> ile virus nucleic acid persistence in whole blood months after clearance in plasma: implication for transfusion and transplantation safety. Transfusion, 2014, 54, 3232-3241.	0.8	68
44	West Nile Virus Infections Projected from Blood Donor Screening Data, United States, 2003. Emerging Infectious Diseases, 2006, 12, 395-402.	2.0	67
45	Distinguishing Secondary Dengue Virus Infection From Zika Virus Infection With Previous Dengue by a Combination of 3 Simple Serological Tests. Clinical Infectious Diseases, 2017, 65, 1829-1836.	2.9	66
46	SARS-CoV-2 induces robust germinal center CD4 T follicular helper cell responses in rhesus macaques. Nature Communications, 2021, 12, 541.	5.8	66
47	Duration of Dengue Viremia in Blood Donors and Relationships Between Donor Viremia, Infection Incidence and Clinical Case Reports During a Large Epidemic. Journal of Infectious Diseases, 2016, 214, 49-54.	1.9	59
48	First cases of Zika virus–infected US blood donors outside states with areas of active transmission. Transfusion, 2017, 57, 770-778.	0.8	59
49	First Zikaâ€positive donations in the continental United States. Transfusion, 2017, 57, 762-769.	0.8	59
50	Beneficial effects of benznidazole in Chagas disease: NIH SaMi-Trop cohort study. PLoS Neglected Tropical Diseases, 2018, 12, e0006814.	1.3	59
51	Emerging infectious agents and the nation's blood supply: responding to potential threats in the 21st century. Transfusion, 2013, 53, 438-454.	0.8	58
52	Electrocardiographic Abnormalities in Trypanosoma cruzi Seropositive and Seronegative Former Blood Donors. PLoS Neglected Tropical Diseases, 2013, 7, e2078.	1.3	57
53	Zika virus: a new threat to the safety of the blood supply with worldwide impact and implications. Transfusion, 2016, 56, 1907-1914.	0.8	52
54	Frequency and duration of plasma CMV viremia in seroconverting blood donors and recipients. Transfusion, 2003, 43, 309-313.	0.8	49

#	Article	IF	CITATIONS
55	Lower-Sensitivity and Avidity Modifications of the Vitros Anti-HIV 1+2 Assay for Detection of Recent HIV Infections and Incidence Estimation. Journal of Clinical Microbiology, 2012, 50, 3968-3976.	1.8	49
56	Dengue in the context of "safe blood―and global epidemiology: to screen or not to screen?. Transfusion, 2012, 52, 1634-1639.	0.8	49
57	Evaluation of Commercially Available High-Throughput SARS-CoV-2 Serologic Assays for Serosurveillance and Related Applications. Emerging Infectious Diseases, 2022, 28, 672-683.	2.0	49
58	Chronological storage age and metabolic age of stored red blood cells: are they the same?. Transfusion, 2019, 59, 1620-1623.	0.8	48
59	Intradonor reproducibility and changes in hemolytic variables during red blood cell storage: results of recall phase of the REDSâ€III RBCâ€Omics study. Transfusion, 2019, 59, 79-88.	0.8	47
60	<scp>SARSâ€CoV</scp> â€2 antibody persistence in <scp>COVID</scp> â€19 convalescent plasma donors: Dependency on assay format and applicability to serosurveillance. Transfusion, 2021, 61, 2677-2687.	0.8	46
61	Prevalence of human immunodeficiency virus <scp>RNA</scp> and antibody in firstâ€ŧime, lapsed, and repeat blood donations across five international regions and relative efficacy of alternative screening scenarios. Transfusion, 2013, 53, 2399-2412.	0.8	44
62	Frequent blood donations alter susceptibility of red blood cells to storage―and stress―nduced hemolysis. Transfusion, 2019, 59, 67-78.	0.8	44
63	Blood, sweat, and tears: Red Blood Cellâ€Omics study objectives, design, and recruitment activities. Transfusion, 2019, 59, 46-56.	0.8	44
64	A highly multiplexed droplet digital PCR assay to measure the intact HIV-1 proviral reservoir. Cell Reports Medicine, 2021, 2, 100243.	3.3	44
65	Relative efficacy of nucleic acid amplification testing and serologic screening in preventing hepatitis C virus transmission risk in seven international regions. Transfusion, 2015, 55, 1195-1205.	0.8	43
66	Transfusion-transmitted viral infections: building bridges to transfusion medicine to reduce risks and understand epidemiology and pathogenesis. Transfusion, 2006, 46, 1624-1640.	0.8	42
67	Multiple-ancestry genome-wide association study identifies 27 loci associated with measures of hemolysis following blood storage. Journal of Clinical Investigation, 2021, 131, .	3.9	42
68	Effector memory differentiation increases detection of replication-competent HIV-l in resting CD4+ T cells from virally suppressed individuals. PLoS Pathogens, 2019, 15, e1008074.	2.1	41
69	Evaluation of a new enzyme-linked immunosorbent assay for detection of Chagas antibody in US blood donors. Transfusion, 2007, 47, 90-96.	0.8	40
70	Antibody levels correlate with detection of <i>Trypanosoma cruzi</i> DNA by sensitive polymerase chain reaction assays in seropositive blood donors and possible resolution of infection over time. Transfusion, 2013, 53, 1257-1265.	0.8	40
71	Cancer Incidence and Mortality in a Cohort of US Blood Donors: A 20-Year Study. Journal of Cancer Epidemiology, 2013, 2013, 1-11.	0.5	40
72	Transmission of Neurodegenerative Disorders Through Blood Transfusion. Annals of Internal Medicine, 2016, 165, 316,	2.0	40

#	Article	IF	CITATIONS
73	Large genome-wide association study identifies three novel risk variants for restless legs syndrome. Communications Biology, 2020, 3, 703.	2.0	40
74	Zika virus RNA and IgM persistence in blood compartments and body fluids: a prospective observational study. Lancet Infectious Diseases, The, 2020, 20, 1446-1456.	4.6	39
75	Epidemiologic and laboratory findings from 3 years of testing United States blood donors for <i>Trypanosoma cruzi</i> . Transfusion, 2012, 52, 1901-1911.	0.8	38
76	Clinical and genetic ancestry profile of a large multi entre sickle cell disease cohort in Brazil. British Journal of Haematology, 2018, 182, 895-908.	1.2	38
77	Rapid, Fully Automated Digital Immunoassay for p24 Protein with the Sensitivity of Nucleic Acid Amplification for Detecting Acute HIV Infection. Clinical Chemistry, 2015, 61, 1372-1380.	1.5	35
78	Relative analytical sensitivity of donor nucleic acid amplification technology screening and diagnostic realâ€ŧime polymerase chain reaction assays for detection of Zika virus RNA. Transfusion, 2017, 57, 734-747.	0.8	34
79	Impact of Anti–PD-1 and Anti–CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study. Clinical Infectious Diseases, 2021, 73, e1973-e1981.	2.9	34
80	Lymphocyte subset analysis on frozen whole blood. , 1997, 29, 340-350.		33
81	Detection of microchimerism by PCR is a function of amplification strategy. Transfusion, 2001, 41, 39-44.	0.8	32
82	The Blood Xenotropic Murine Leukemia Virus–Related Virus Scientific Research Working Group: mission, progress, and plans. Transfusion, 2011, 51, 643-653.	0.8	32
83	Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. Gastroenterology, 2019, 156, 1496-1507.e7.	0.6	32
84	HIV antiretroviral therapy and prevention use in US blood donors: a new blood safety concern. Blood, 2020, 136, 1351-1358.	0.6	32
85	Use of US Blood Donors for National Serosurveillance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: Basis for an Expanded National Donor Serosurveillance Program. Clinical Infectious Diseases, 2022, 74, 871-881.	2.9	32
86	A novel antibody surrogate biomarker to monitor parasite persistence in Trypanosoma cruzi-infected patients. PLoS Neglected Tropical Diseases, 2018, 12, e0006226.	1.3	32
87	Serologic screening of United States blood donors for <i>Babesia microti</i> using an investigational enzyme immunoassay. Transfusion, 2016, 56, 1866-1874.	0.8	31
88	Establishing assay cutoffs for HLA antibody screening of apheresis donors. Transfusion, 2011, 51, 2092-2101.	0.8	30
89	Zika Virus-Immune Plasmas from Symptomatic and Asymptomatic Individuals Enhance Zika Pathogenesis in Adult and Pregnant Mice. MBio, 2019, 10, .	1.8	30
90	Development and evaluation of a transfusion medicine genome wide genotyping array. Transfusion, 2019, 59, 101-111.	0.8	30

6

#	Article	IF	CITATIONS
91	Donor genetic and nongenetic factors affecting red blood cell transfusion effectiveness. JCI Insight, 2022, 7, .	2.3	29
92	Screening the Blood Supply for Zika Virus in the 50 U.S. States and Puerto Rico. Annals of Internal Medicine, 2019, 170, 164.	2.0	28
93	Enhanced classification of Chagas serologic results and epidemiologic characteristics of seropositive donors at three large blood centers in Brazil. Transfusion, 2010, 50, 2628-2637.	0.8	25
94	Discovery of False Elite Controllers: HIV Antibody-Positive RNA-Negative Blood Donors Found To Be on Antiretroviral Therapy. Journal of Infectious Diseases, 2019, 220, 643-647.	1.9	25
95	Serosurveillance for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Incidence Using Global Blood Donor Populations. Clinical Infectious Diseases, 2021, 72, 254-256.	2.9	25
96	Risk assessment and cost-effectiveness/utility analysis. Biologicals, 2009, 37, 78-87.	0.5	23
97	Infection Staging and Incidence Surveillance Applications of High Dynamic Range Diagnostic Immuno-Assay Platforms. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 547-555.	0.9	23
98	In Situ <i>Hybridization and Immunocytochemistry for Improved Assessment of Human Immunodeficiency Virus Cultures</i> . American Journal of Clinical Pathology, 1987, 88, 673-680.	0.4	22
99	Assessing intra-lab precision and inter-lab repeatability of outgrowth assays of HIV-1 latent reservoir size. PLoS Computational Biology, 2019, 15, e1006849.	1.5	22
100	Piloting and implementation of quality assessment and quality control procedures in RBCâ€Omics: a large multiâ€center study of red blood cell hemolysis during storage. Transfusion, 2019, 59, 57-66.	0.8	22
101	Distribution of parvovirus B19 DNA in blood compartments and persistence of virus in blood donors. Transfusion, 2011, 51, 1896-1908.	0.8	21
102	HIV incidence in US first-time blood donors and transfusion risk with a 12-month deferral for men who have sex with men. Blood, 2020, 136, 1359-1367.	0.6	21
103	Social Vulnerability and Rurality Associated With Higher Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection–Induced Seroprevalence: A Nationwide Blood Donor Study—United States, July 2020–June 2021. Clinical Infectious Diseases, 2022, 75, e133-e143.	2.9	21
104	Sepsis from an apheresis platelet contaminated with <scp><i>Acinetobacter calcoaceticus/baumannii</i></scp> complex bacteria and <scp><i>Staphylococcus saprophyticus</i></scp> after pathogen reduction. Transfusion, 2020, 60, 1960-1969.	0.8	20
105	Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA-licensed assays: implications for transfusion safety and HCV infection outcomes. Blood, 2012, 119, 6326-6334.	0.6	19
106	Assessment of nucleic acid modification induced by amotosalen and ultraviolet A light treatment of platelets and plasma using realâ€ŧime polymerase chain reaction amplification of variable length fragments of mitochondrial DNA. Transfusion, 2016, 56, 410-420.	0.8	19
107	Performance comparison of the Maxim and Sedia Limiting Antigen Avidity assays for HIV incidence surveillance. PLoS ONE, 2019, 14, e0220345.	1.1	19
108	Quantitation of residual WBCs in filtered blood components by high-throughput, real-time kinetic PCR. Transfusion, 2002, 42, 87-93.	0.8	18

#	Article	IF	CITATIONS
109	A generalizable method for estimating duration of HIV infections using clinical testing history and HIV test results. Aids, 2019, 33, 1231-1240.	1.0	18
110	Assessing the Suitability of Next-Generation Viral Outgrowth Assays to Measure Human Immunodeficiency Virus 1 Latent Reservoir Size. Journal of Infectious Diseases, 2021, 224, 1209-1218.	1.9	18
111	Selecting COVID â€19 convalescent plasma for neutralizing antibody potency using a highâ€capacity SARSâ€CoV â€2 antibody assay. Transfusion, 2021, 61, 1160-1170.	0.8	18
112	Incidence and Predictors of Progression to Chagas Cardiomyopathy: Long-Term Follow-Up of <i>Trypanosoma cruzi</i> –Seropositive Individuals. Circulation, 2021, 144, 1553-1566.	1.6	18
113	Impact of oneâ€ŧime testing for <i>Trypanosoma cruzi</i> antibodies among blood donors in the United States. Transfusion, 2019, 59, 1016-1023.	0.8	17
114	Evolving viral and serological stages of Zika virus RNA-positive blood donors and estimation of incidence of infection during the 2016 Puerto Rican Zika epidemic: an observational cohort study. Lancet Infectious Diseases, The, 2020, 20, 1437-1445.	4.6	17
115	Increased Frequency of Tim-3 Expressing T Cells Is Associated with Symptomatic West Nile Virus Infection. PLoS ONE, 2014, 9, e92134.	1.1	17
116	Correlation of West Nile Virus Incidence in Donated Blood with West Nile Neuroinvasive Disease Rates, United States, 2010–2012. Emerging Infectious Diseases, 2017, 23, 212-219.	2.0	16
117	The Recipient Epidemiology and Donor Evaluation <scp>Studyâ€Nâ€Pediatric</scp> ( <scp>REDSâ€Nâ€P</scp> ): research program striving to improve blood donor safety and optimize transfusion outcomes across the lifespan. Transfusion, 2022, 62, 982-999.	A 0.8	16
118	Frequent detection but lack of infectivity of SARS-CoV-2 RNA in presymptomatic, infected blood donor plasma. Journal of Clinical Investigation, 2022, 132, .	3.9	16
119	Characteristics of Antibody Responses in West Nile Virus-Seropositive Blood Donors. Journal of Clinical Microbiology, 2014, 52, 57-60.	1.8	15
120	Additive effects of blood donor smoking and gamma irradiation on outcome measures of red blood cell transfusion. Transfusion, 2020, 60, 1175-1182.	0.8	15
121	SARS-CoV-2 Infection of Rhesus Macaques Treated Early with Human COVID-19 Convalescent Plasma. Microbiology Spectrum, 2021, 9, e0139721.	1.2	15
122	Reinfection by the SARS-CoV-2 Gamma variant in blood donors in Manaus, Brazil. BMC Infectious Diseases, 2022, 22, 127.	1.3	15
123	Analysis of maternal microchimerism in rhesus monkeys ( <i>Macaca mulatta</i> ) using real-time quantitative PCR amplification of MHC polymorphisms. Chimerism, 2014, 5, 6-15.	0.7	14
124	Arbovirus Diagnostics: From Bad to Worse due to Expanding Dengue Virus Vaccination and Zika Virus Epidemics. Clinical Infectious Diseases, 2018, 66, 1181-1183.	2.9	14
125	Genetic Characterization of a Panel of Diverse HIV-1 Isolates at Seven International Sites. PLoS ONE, 2016, 11, e0157340.	1.1	13
126	A Child's HLA-DRB1 genotype increases maternal risk of systemic lupus erythematosus. Journal of Autoimmunity, 2016, 74, 201-207.	3.0	12

#	Article	IF	CITATIONS
127	<i>Editorial Commentary</i> : Timing Is Everything: Shortcomings of Current HIV Diagnostics in the Early Treatment Era. Clinical Infectious Diseases, 2016, 63, 562-564.	2.9	12
128	Automated Multireplicate Quantification of Persistent HIV-1 Viremia in Individuals on Antiretroviral Therapy. Journal of Clinical Microbiology, 2020, 58, .	1.8	11
129	Distinct SARS-CoV-2 antibody reactivity patterns in coronavirus convalescent plasma revealed by a coronavirus antigen microarray. Scientific Reports, 2021, 11, 7554.	1.6	11
130	Declining antibody levels to Trypanosoma cruzi correlate with polymerase chain reaction positivity and electrocardiographic changes in a retrospective cohort of untreated Brazilian blood donors. PLoS Neglected Tropical Diseases, 2020, 14, e0008787.	1.3	11
131	Seroconverting Blood Donors as a Resource for Characterising and Optimising Recent Infection Testing Algorithms for Incidence Estimation. PLoS ONE, 2011, 6, e20027.	1.1	10
132	Lessons and opportunities from epidemiologic and molecular investigations of infected blood donors. Transfusion, 2006, 46, 1663-1666.	0.8	9
133	Minimal infectious dose and dynamics of <i>Babesia microti</i> parasitemia in a murine model. Transfusion, 2018, 58, 2903-2910.	0.8	9
134	Development of an international external quality assurance program for HIV-1 incidence using the Limiting Antigen Avidity assay. PLoS ONE, 2019, 14, e0222290.	1.1	9
135	Sex hormone intake in female blood donors: impact on haemolysis during cold storage and regulation of erythrocyte calcium influx by progesterone. Blood Transfusion, 2019, 17, 263-273.	0.3	9
136	Bimodal distribution of <scp><i>T</i></scp> <i>rypanosoma cruzi</i> antibody levels in blood donors from a highly endemic area of <scp>A</scp> rgentina: what is the significance of lowâ€reactive samples?. Transfusion, 2015, 55, 2499-2504.	0.8	8
137	Detection of host immune responses in acute phase sera of spontaneous resolution versus persistent hepatitis C virus infection. Journal of General Virology, 2012, 93, 1673-1679.	1.3	8
138	Proteome-Wide Zika Virus CD4 T Cell Epitope and HLA Restriction Determination. ImmunoHorizons, 2020, 4, 444-453.	0.8	8
139	Antibody profiles in <scp>COVID</scp> â€19 convalescent plasma prepared with amotosalen/ <scp>UVA</scp> pathogen reduction treatment. Transfusion, 2022, 62, 570-583.	0.8	8
140	Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity had no antiviral effects but moderately reduced lung inflammation. PLoS Pathogens, 2022, 18, e1009925.	2.1	8
141	Impact of prior Dengue immunity on Zika vaccine protection in rhesus macaques and mice. PLoS Pathogens, 2021, 17, e1009673.	2.1	7
142	Vaccination of <scp>COVID</scp> â€19 convalescent plasma donors increases binding and neutralizing antibodies against <scp>SARSâ€CoV</scp> â€2 variants. Transfusion, 2022, 62, 563-569.	0.8	7
143	The Specificity of the Persistent IgM Neutralizing Antibody Response in Zika Virus Infections among Individuals with Prior Dengue Virus Exposure. Journal of Clinical Microbiology, 2021, 59, e0040021.	1.8	6
144	Trans-ancestral fine-mapping of MHC reveals key amino acids associated with spontaneous clearance of hepatitis C in HLA-DQl²1. American Journal of Human Genetics, 2022, 109, 299-310.	2.6	6

#	Article	IF	CITATIONS
145	Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2. Nature Communications, 2022, 13, 2451.	5.8	6
146	The Impact of Early Antiretroviral Treatment (ART) for HIV on the Sensitivity of the Latest Generation of Blood Screening and Point of Care Assays. Viruses, 2022, 14, 1426.	1.5	6
147	Simultaneous estimation of detection sensitivity and absolute copy number from digital PCR serial dilution. Computational Biology and Chemistry, 2017, 68, 1-5.	1.1	5
148	Multi-ancestry fine mapping of interferon lambda and the outcome of acute hepatitis C virus infection. Genes and Immunity, 2020, 21, 348-359.	2.2	5
149	Association of proton pump inhibitor and histamine H2-receptor antagonists with restless legs syndrome. Sleep, 2021, 44, .	0.6	5
150	Erratum to "Cancer Incidence and Mortality in a Cohort of US Blood Donors: A 20-Year Study― Journal of Cancer Epidemiology, 2014, 2014, 1-2.	0.5	4
151	Association of HIV infection with clinical and laboratory characteristics of sickle cell disease. BMC Infectious Diseases, 2020, 20, 638.	1.3	4
152	Identification of Anti-Premembrane Antibody as a Serocomplex-Specific Marker To Discriminate Zika, Dengue, and West Nile Virus Infections. Journal of Virology, 2021, 95, e0061921.	1.5	4
153	<i>How do we</i> â€ form and coordinate a national serosurvey of SARS oVâ€2 within the blood collection industry?. Transfusion, 0, , .	0.8	4
154	A novel high performing multiplex immunoassay Multi-HTLV for serological confirmation and typing of HTLV infections. PLoS Neglected Tropical Diseases, 2021, 15, e0009925.	1.3	3
155	Four decades of <scp>HIV</scp> and transfusion safety: Much accomplished but ongoing challenges. Transfusion, 2022, 62, 1334-1339.	0.8	3
156	Sex-specific genetic modifiers identified susceptibility of cold stored red blood cells to osmotic hemolysis. BMC Genomics, 2022, 23, 227.	1.2	2
157	Retroviruses. , 0, , 59-66.		1
158	First "themed issue―of TRANSFUSION on thirty years of progress in blood safety since recognition of transfusion-associated AIDS. Transfusion, 2013, 53, 2357-2358.	0.8	1
159	First "themed issue―of TRANSFUSION on thirty years of progress in blood safety since recognition of transfusion-associated AIDS. Transfusion, 2013, 53, 2120-2121.	0.8	1
160	Pharmacogenomic Profile and Adverse Drug Reactions in a Prospective Therapeutic Cohort of Chagas Disease Patients Treated with Benznidazole. International Journal of Molecular Sciences, 2021, 22, 1960.	1.8	1
161	Challenges to the performance of current HIV diagnostic assays and the need for centralized specimen archives: a review of the Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA) repository. Gates Open Research, 2019, 3, 1511.	2.0	1
162	Clinical Protection During the First Omicron Wave in Unvaccinated, Convalescent US Adults. JAMA - Journal of the American Medical Association, 2022, 328, 212.	3.8	1

#	Article	IF	CITATIONS
163	Effect of recipient immune status on the persistence and clinical consequences of transfused leucocytes. ISBT Science Series, 2007, 2, 196-203.	1.1	0
164	Herbert Asa Perkins, MD. Transfusion, 2013, 53, n/a-n/a.	0.8	0
165	Remembering James W. Mosley, MD (1929â€2015), and his legacy in transfusion safety. Transfusion, 2016, 56, 996-998.	0.8	0
166	A cytotoxic-skewed immune set point predicts low neutralizing antibody levels after Zika virus infection. Cell Reports, 2022, 39, 110815.	2.9	0